BioNTech (BNTX) CEO Ugur Sahin details major share and option stake
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
BioNTech SE Chief Executive Officer Ugur Sahin filed an initial ownership report detailing his direct, indirect and derivative interests in the company’s ordinary shares. The filing shows indirect ownership of 40,132,788 ordinary shares held through Medine GmbH, which he wholly owns and may be deemed to beneficially own. It also lists 858,209 ordinary shares held directly.
In addition, Sahin holds several option and phantom option awards and performance share units tied to BioNTech ordinary shares, with various exercise prices and expiration dates extending to 2035. These awards generally vest in equal annual installments over four years and are subject to performance-based and other conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Sahin Ugur
Role
Chief Executive Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Phantom Option | -- | -- | -- |
| holding | Performance Share Unit | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 38,506 shares (Direct);
Phantom Option — 17,780 shares (Direct);
Performance Share Unit — 23,434 shares (Direct);
Ordinary Shares — 40,132,788 shares (Indirect, See Footnote);
Ordinary Shares — 858,209 shares (Direct)
Footnotes (1)
- The ordinary shares are held by Medine GmbH. The Reporting Person is the sole shareholder of Medine GmbH. 1,021,398 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The Reporting Person may be deemed to beneficially own the ordinary shares held by Medine GmbH. The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions. The option may be settled in ordinary shares, American Depositary Shares ("ADSs") and/or cash at the election of the supervisory board. Subject to adjustment such that the trading price of an ADS as of an exercise date does not exceed 800% of the grant date exercise price. The exercise price of this option is EUR 75.91. The exercise price of this option is EUR 93.35. Each phantom option represents the right to receive a cash payment equal to the difference between an exercise closing price (average closing price of an ADS over the last ten trading days preceding the exercise date) and the exercise price. Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.
FAQ
What does Ugur Sahin’s Form 3 filing for BioNTech (BNTX) show?
The Form 3 shows Ugur Sahin’s initial ownership in BioNTech, including direct and indirect ordinary shares and multiple option, phantom option, and performance share unit awards with long-dated expirations and performance-based vesting conditions tied to the company’s ordinary share performance.